ONO 7914
Alternative Names: ONO-7914Latest Information Update: 03 Mar 2022
At a glance
- Originator Ono Pharmaceutical
- Class Antineoplastics
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 09 Feb 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in Japan (Parenteral) (jRCT2031210530) (NCT06535009) (Ono Pharmaceutical pipeline, February 2022)
- 31 Jan 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Japan (Parenteral) (jRCT2031210530) (NCT06535009) (Ono Pharmaceutical pipeline, February 2022)
- 31 Jan 2022 Preclinical trials in Solid tumours in Japan (Parenteral) before Janaury 2022 (Ono Pharmaceutical pipeline, February 2022)